Bayer's Checkbook and Its Pipeline Are Moving on Separate Timetables

Bayer has been busy on two fronts that investors often blur together: building physical capacity and pushing molecules through regulators. The German group said on October 2 that it will sink 2.2 billion US dollars into a new pharmaceutical production site in New Albany, Ohio, a facility expected to generate roughly 600 jobs. Ten days earlier, the US Food and Drug Administration had already accepted its supplemental application for finerenone, marketed as Kerendia, for adults with chronic kidney disease who do not have diabetes.

Those two announcements describe entirely different stages of the value chain. A site decision is a capital plan; an accepted filing is a regulatory checkpoint. Neither is a revenue line.

What the FDA's acceptance does — and doesn't — mean

The Kerendia submission rests on positive results from the Phase III FIND-CKD trial. Acceptance confirms the agency will review the file; it does not grant the expanded indication. Bayer disclosed the FDA's move on October 8, roughly two weeks after the Ohio investment was unveiled.

Separately, the company's wholly owned but independently run subsidiary Vividion Therapeutics began a global Phase II study on October 15 pairing VVD-214 with pembrolizumab. The trial is slated to enroll about 140 patients across study centers in some 21 countries, targeting previously untreated advanced colorectal cancer with MSI-high or dMMR characteristics. That patient definition matters: the launch says nothing about colorectal cancer at large, and the planned enrollment is not a completed recruitment.

Two brokers, two price targets, one calendar

JPMorgan reaffirmed its "Overweight" rating and a 61-euro price target on October 16, keeping a constructive stance heading into the quarterly numbers. UBS had held Bayer at "Buy" with a 62-euro target a day earlier, citing persistent Crop Science trends for 2026 and 2027 alongside momentum in pharmaceuticals — a reminder that the bull case is not purely a pharma story.

Both figures are analyst expectations, not company guidance, and neither substitutes for a look at operating performance. Development news sketches future opportunity; quarterly figures show what a reporting period actually delivered.

That reckoning comes on November 3, when Bayer publishes its interim report for the third quarter of 2026. Until then, the gap between announced capacity, regulatory progress and reported business performance is where the investment case has to be judged. The Ohio plant and the finerenone filing offer concrete markers — but they do not pre-empt the results.